問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital

Division of General Internal Medicine

Division of Hematology & Oncology

更新時間：2024-02-21

傅蓓安
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

27Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

傅蓓安

List

28Cases

2024-02-28 - 2030-03-31

Phase III

Active
A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients with Peripheral T-Cell Lymphoma

  • Condition/Disease

    Peripheral T-Cell Lymphoma

  • Test Drug

    injection

Participate Sites
6Sites

Recruiting6Sites

2024-12-26 - 2028-10-20

Phase III

Active
A Phase 3, Open-Label, Randomized, Multinational Study to Investigate the Anti-tumor Efficacy of Golidocitinib versus Investigator’s Choice in Adult Patients with Relapsed/Refractory Peripheral T-cell Lymphoma

  • Condition/Disease

    Relapsed/Refractory Peripheral T-cell Lymphoma

  • Test Drug

    injective

Participate Sites
8Sites

Recruiting8Sites

2025-01-17 - 2032-06-14

Phase III

Not yet recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW)

  • Condition/Disease

    Myelodysplastic Syndromes

  • Test Drug

    注射液劑(無菌製備)

Participate Sites
6Sites

Recruiting6Sites

2024-12-01 - 2032-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2023-07-01 - 2029-07-01

Phase III

Active
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator's Choice in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-1)

  • Condition/Disease

    Follicular Lymphoma (FL)

  • Test Drug

    Odronextamab

Participate Sites
12Sites

Recruiting12Sites

2024-12-30 - 2031-06-26

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-02-01 - 2038-01-31

Phase III

A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)

  • Condition/Disease

    Follicular Lymphoma (FL)

  • Test Drug

    EpcoritamabLenalidomideObinutuzumab RituximabCyclophosphamideDoxorubicinVincristineVincristinePrednisoneBendamustine

Participate Sites
4Sites

Recruiting4Sites

2023-10-20 - 2026-12-31

Phase I

A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

  • Condition/Disease

    B-cell Non Hodgkin Lymphoma、 Diffuse Large B Cell Lymphoma 、High-grade B-cell Lymphoma、 Follicular Lymphoma

  • Test Drug

    AZD0486

Participate Sites
4Sites

Recruiting4Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB